Background
There are no effective vaccines against
Babesia
and
Theileria
parasites; therefore, therapy depends heavily on antiprotozoal drugs. Treatment options for piroplasmosis are limited; thus, the need for new antiprotozoal agents is becoming increasingly urgent. Ellagic acid (EA) is a polyphenol found in various plant products and has antioxidant, antibacterial and effective antimalarial activity
in vitro
and
in vivo
without toxicity. The present study documents the efficacy of EA and EA-loaded nanoparticles (EA-NPs) on the growth of
Babesia
and
Theileria
.
Methods
In this study, the inhibitory effect of EA, β-cyclodextrin ellagic acid (β-CD EA) and antisolvent precipitation with a syringe pump prepared ellagic acid (APSP EA) was evaluated on four
Babesia
species and
Theileria equi in vitro
, and on the multiplication of
B. microti
in mice. The cytotoxicity assay was tested on Madin-Darby bovine kidney (MDBK), mouse embryonic fibroblast (NIH/3T3) and human foreskin fibroblast (HFF) cell lines.
Results
The half-maximal inhibitory concentration (IC
50
) values of EA and β-CD EA on
B. bovis
,
B. bigemina
,
B. divergens
,
B. caballi
and
T. equi
were 9.58 ± 1.47, 7.87 ± 5.8, 5.41 ± 2.8, 3.29 ± 0.42 and 7.46 ± 0.6 µM and 8.8 ± 0.53, 18.9 ± 0.025, 11 ± 0.37, 4.4 ± 0.6 and 9.1 ± 1.72 µM, respectively. The IC
50
values of APSP EA on
B. bovis
,
B. bigemina
,
B. divergens
,
B. caballi
and
T. equi
were 4.2 ± 0.42, 9.6 ± 0.6, 2.6 ± 1.47, 0.92 ± 5.8 and 7.3 ± 0.54 µM, respectively. A toxicity assay showed that EA, β-CD EA and APSP EA affected the viability of cells with a half-maximal effective concentration (EC
50
) higher than 800 µM. In the experiments on mice, APSP EA at a concentration of 70 mg/kg reduced the peak parasitemia of
B
.
microti
by 68.1%. Furthermore, the APSP EA-atovaquone (AQ) combination showed a higher chemotherapeutic effect than that of APSP EA monotherapy.
Conclusions
To our knowledge, this is the first study to demonstrate the
in vitro
and
in vivo
antibabesial action of EA-NPs and thus supports the use of nanoparticles as an alternative antiparasitic agent.
Electronic supplementary material
The online version of this article (10.1186/s13071-019-3520-x) contains supplementary ma...